Annamycin anthracycline analog data

ARNX announced preliminary results of its Phase I dose-escalating safety trial of Annamycin in 30 patients with multi-drug resistant tumors. The patients primarily had breast, lung or colon cancer or melanoma. Patients who had failed all previous therapy were given Annamycin at doses ranging from 15-240 mg/m 2 once every 3 weeks for up to 6 courses. The dose limiting effect in 2 of 4 patients at the highest dose level was a low platelet count.

ARNX reported no cardiotoxicity, hair loss, inflammation of mucus membranes or skin reactions, adverse responses which are associated with anthracycline drugs. ...